Journal of Chemistry
5
Conflict of Interests
[14] A. A. Weekes and A. D. Westwell, “2-Arylbenzothiazole as
a privileged scaffold in drug discovery,” Current Medicinal
Chemistry, vol. 16, no. 19, pp. 2430–2440, 2009.
[15] S. H. L. Kok, R. Gambari, C. H. Chui et al., “Synthesis and
anti-cancer activity of benzothiazole containing phthalimide on
human carcinoma cell lines,” Bioorganic & Medicinal Chemistry,
vol. 16, no. 7, pp. 3626–3631, 2008.
e authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgment
[16] Z. Wang, X.-H. Shi, J. Wang et al., “Synthesis, structure-
activity relationships and preliminary antitumor evaluation of
benzothiazole-2-thiol derivatives as novel apoptosis inducers,”
Bioorganic & Medicinal Chemistry Letters, vol. 21, no. 4, pp.
1097–1101, 2011.
[17] S. Xuejiao, X. Yong, W. Ningyu et al., “A novel benzothiazole
derivative YLT322 induces apoptosis via the mitochondrial
apoptosis pathway in vitro with anti-tumor activity in solid
malignancies,” PLoS ONE, vol. 8, no. 5, Article ID e63900, 2013.
[18] D. Armenise, A. Carocci, A. Catalano et al., “Synthesis and
antimicrobial evaluation of a new series of N-1,3-benzothiazol-
2-ylbenzamides,” Journal of Chemistry, vol. 2013, Article ID
181758, 7 pages, 2013.
[19] D. Armenise, N. De Laurentis, A. Reho, A. Rosato, and F.
Morlacchi, “Synthesis and antifungal activity against strains of
Candida albicans of 6-fluoro-4(5 or 7)-chloro-2-(difluoroben-
zoyl)aminobenzothiazoles,” Journal of Heterocyclic Chemistry,
vol. 41, no. 5, pp. 771–775, 2004.
[20] A. Carocci, A. Catalano, C. Bruno et al., “Synthesis and in vitro
sodium channel blocking activity evaluation of novel homochi-
ral mexiletine analogs,” Chirality, vol. 22, no. 3, pp. 299–307,
2010.
[21] A. Catalano, A. Carocci, M. M. Cavalluzzi et al., “Hydroxylated
analogs of mexiletine as tools for structural-requirements inves-
tigation of the sodium channel blocking activity,” Archiv der
Pharmazie, vol. 343, no. 6, pp. 325–332, 2010.
[22] A. Catalano, R. Budriesi, C. Bruno et al., “Searching for new
antiarrhythmic agents: evaluation of meta-hydroxymexiletine
enantiomers,” European Journal of Medicinal Chemistry, vol. 65,
pp. 511–516, 2013.
is work was accomplished thanks to financial support of
the Ministero dell’Istruzione, dell’Universita` e della Ricerca
(MIUR).
References
[1] C. Dive and J. A. Hickman, “Drug-target interactions: only the
first step in the commitment to a programmed cell death?”
British Journal of Cancer, vol. 64, no. 1, pp. 192–196, 1991.
[2] J. F. R. Kerr, C. M. Winterford, and B. V. Harmon, “Apoptosis: its
significance in cancer and cancer therapy,” Cancer, vol. 73, no.
8, pp. 2013–2026, 1994.
[3] C. Saturnino, C. Palladino, M. Napoli et al., “Synthesis and bio-
logical evaluation of new N-alkylcarbazole derivatives as STAT3
inhibitors: preliminary study,” European Journal of Medicinal
Chemistry, vol. 60, pp. 112–119, 2013.
[4] J. Cummings, T. H. Ward, M. Ranson, and C. Dive, “Apop-
tosis pathway-targeted drugs—from the bench to the clinic,”
Biochimica et Biophysica Acta, vol. 1705, no. 1, pp. 53–66, 2004.
[5] P. S. Yadav, Devprakash, and G. P. Senthilkumar, “Benzoth-
iazole: different methods of synthesis and diverse biological
activities,” International Journal of Pharmaceutical Science and
Drug Research, vol. 3, no. 1, pp. 1–7, 2011.
[6] C. Bruno, A. Carocci, A. Catalano et al., “Facile, alternative route
to lubeluzole, its enantiomer, and the racemate,” Chirality, vol.
18, no. 4, pp. 227–231, 2006.
[7] I. Hutchinson, T. D. Bradshaw, C. S. Matthews, M. F. G. Stevens,
and A. D. Westwell, “Antitumour benzothiazoles. Part 20: 3ꢂ-
cyano and 3ꢂ-alkynyl-substituted 2-(4ꢂ-aminophenyl)benzothi-
azoles as new potent and selective analogues,” Bioorganic &
Medicinal Chemistry Letters, vol. 13, no. 3, pp. 471–474, 2003.
[8] A. Catalano, A. Carocci, I. Defrenza et al., “2-Aminoben-
zothiazole derivatives: search for new antifungal agents,” Euro-
pean Journal of Medicinal Chemistry, vol. 64, pp. 357–364, 2013.
[23] A. Carocci, A. Catalano, C. Bruno et al., “N-(phenox-
yalkyl)amides as MT and MT ligands: antioxidant properties
1
2
and inhibition of Ca2+/CaM-dependent kinase II,” Bioorganic &
Medicinal Chemistry, vol. 21, no. 4, pp. 847–851, 2013.
[24] A. Catalano, J.-F. Desaphy, G. Lentini et al., “Synthesis and
toxicopharmacological evaluation of m-hydroxymexiletine, the
first metabolite of mexiletine more potent than the parent com-
pound on voltage-gated sodium channels,” Journal of Medicinal
Chemistry, vol. 55, no. 3, pp. 1418–1422, 2012.
[9] C. Franchini, M. Muraglia, F. Corbo et al., “Synthesis and
anti-cancer activity of benzothiazole containing phthalimide on
human carcinoma cell lines,” Archiv der Pharmazie, vol. 342, no.
7, pp. 605–613, 2009.
[10] I. Defrenza, A. Catalano, A. Carocci et al., “1,3-Benzothiazoles
as antimicrobial agents,” Journal of Heterociclic Chemistry, vol.
52, pp. 1705–1712, 2015.
[11] P. C. Sharma, A. Sinhmar, A. Sharma, H. Rajak, and D. P. Pathak,
“Medicinal significance of benzothiazole scaffold: an insight
view,” Journal of Enzyme Inhibition and Medicinal Chemistry,
vol. 28, no. 2, pp. 240–266, 2013.
[12] P. Chaudhary, P. K. Sharma, A. Sharma, and J. Varshney,
“Recent advances in pharmacological activity of benzothiazole
derivatives,” International Journal of Current Pharmaceutical
Research, vol. 2, no. 4, pp. 5–11, 2010.
[13] K. Ahmed, S. Y. V. Venkata, N. A. K. Mohammed, F. Sultana, and
K. R. Methuku, “Recent advances on structural modifications
of benzothiazoles and their conjugate systems as potential
chemotherapeutics,” Expert Opinion on Investigational Drugs,
vol. 21, no. 5, pp. 619–635, 2012.